You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMilnacipran
Accession NumberDB04896
TypeSmall Molecule
GroupsApproved
DescriptionMilnacipran is an antidepressant of the serotonin-norepinephrine reuptake inhibitor class. It more potently inhibits norepinephrine uptake than serotonin. It is provided as a racemic mixture. FDA approved in January 2009.
Structure
Thumb
Synonyms
(-)-milnacipran
Midalcipran
Milnacipran
Milnacipranum
External Identifiers
  • F2207
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Savellatablet, film coated100 mg/1oralSTAT Rx USA LLC2009-04-17Not applicableUs
SavellakitoralForest Laboratories, Inc.2009-04-17Not applicableUs
Savellatablet, film coated50 mg/1oralCardinal Health2009-04-17Not applicableUs
Savellatablet, film coated25 mg/1oralLake Erie Medical DBA Quality Care Products LLC2009-04-17Not applicableUs
Savellatablet, film coated50 mg/1oralForest Laboratories, Inc.2009-04-17Not applicableUs
Savellatablet, film coated25 mg/1oralRebel Distributors Corp2009-04-17Not applicableUs
Savellatablet, film coated100 mg/1oralForest Laboratories, Inc.2009-04-17Not applicableUs
Savellatablet, film coated25 mg/1oralUnit Dose Services2009-04-17Not applicableUs
Savellatablet, film coated25 mg/1oralSTAT Rx USA LLC2009-04-17Not applicableUs
Savellatablet, film coated50 mg/1oralRebel Distributors Corp2009-04-17Not applicableUs
Savellatablet, film coated12.5 mg/1oralForest Laboratories, Inc.2009-04-17Not applicableUs
Savellatablet, film coated100 mg/1oralPhysicians Total Care, Inc.2010-01-19Not applicableUs
Savellatablet, film coated50 mg/1oralSTAT Rx USA LLC2009-04-17Not applicableUs
Savellatablet, film coated50 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-17Not applicableUs
Savellatablet, film coated25 mg/1oralForest Laboratories, Inc.2009-04-17Not applicableUs
Savellatablet, film coated50 mg/1oralPhysicians Total Care, Inc.2009-06-22Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Milnacipran Hydrochloridetablet, film coated12.5 mg/1oralRanbaxy Pharmaceuticals Inc.2014-11-27Not applicableUs
Milnacipran Hydrochloridetablet, film coated25 mg/1oralRanbaxy Pharmaceuticals Inc.2014-11-27Not applicableUs
Milnacipran Hydrochloridetablet, film coated50 mg/1oralRanbaxy Pharmaceuticals Inc.2014-11-27Not applicableUs
Milnacipran Hydrochloridetablet, film coated100 mg/1oralRanbaxy Pharmaceuticals Inc.2014-11-27Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Dalcipran Not Available
IxelNot Available
ToledominNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Milnacipran Hydrochloride
Thumb
  • InChI Key: XNCDYJFPRPDERF-PBCQUBLHSA-N
  • Monoisotopic Mass: 282.149891075
  • Average Mass: 282.809
DBSALT000119
Categories
UNIIG56VK1HF36
CAS number92623-85-3
WeightAverage: 246.348
Monoisotopic: 246.173213336
Chemical FormulaC15H22N2O
InChI KeyInChIKey=GJJFMKBJSRMPLA-HIFRSBDPSA-N
InChI
InChI=1S/C15H22N2O/c1-3-17(4-2)14(18)15(10-13(15)11-16)12-8-6-5-7-9-12/h5-9,13H,3-4,10-11,16H2,1-2H3/t13-,15+/m1/s1
IUPAC Name
(1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide
SMILES
CCN(CC)C(=O)[C@@]1(C[C@@H]1CN)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylacetamides. These are amide derivatives of phenylacetic acids.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylacetamides
Direct ParentPhenylacetamides
Alternative Parents
Substituents
  • Phenylacetamide
  • Aralkylamine
  • Cyclopropanecarboxylic acid or derivatives
  • Tertiary carboxylic acid amide
  • Tertiary amine
  • Carboxamide group
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Primary aliphatic amine
  • Carbonyl group
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationMilnacipran is used to treat moderate to severe clinical depression but this indication is not yet FDA-approved in the USA. Milnacipran is labelled for the treatment of fibromyalgia pain.
PharmacodynamicsAlthough milnacipran prolongs the QTc interval, the increase is not considered clinically significant.
Mechanism of actionMilnacipran inhibits norepinephrine and serotonin reuptake in a 3:1 ratio, in practical use this means a balanced (equal) action upon both transmitters. The serotonin reuptake inhibition is likely to improve depression, while the norepinephrine reuptake inihibition probably improves chronic pain. Milnacipran exerts no significant actions on postynaptic H1, alpha-1, D1, D2, and muscarinic receptors, as well as on benzodiazepine/opiate binding sites. [Wikipedia]
Related Articles
AbsorptionMilnacipran is well absorbed following oral administration with an absolute bioavailability of 85-90%. Meals have no effect on absorption. Peak concentrations occur 2 -4 hours post-administration and is delayed in elderly patients. Time to steady state = 36 - 48 hours;
Volume of distribution

400 L, following a single IV dose to a healthy subject.

Protein bindingPlasma protein binding is 13%.
Metabolism

Hepatic metabolism of milnacipran occurs via glucuronidation. No involvement of CYP450 isozymes or active metabolites found.

Route of eliminationIt is excreted predominantly unchanged in urine (50%- 60%, 24% as l-milnacipran and 31% as d-milnacipran). The l-milnacipran carbamoyl-O-glucuronide was the major metabolite excreted in urine and accounted for approximately 17% of the dose; approximately 2% of the dose was excreted in urine as d-milnacipran carbamoyl-O-glucuronide. Approximately 8% of the dose was excreted in urine as the N-desethyl milnacipran metabolite.
Half lifeThe terminal elimination half-life, when given to healthy subjects is 6-8 hours. When given to severe renal impairment patients is 7 - 10 hours. The active enantiomer, d-milnacipran, has a longer elimination half-life (8-10 hours) than the l-enantiomer (4-6 hours).
ClearanceNot Available
ToxicityLD50, oral, rat: 213 mg/kg. The most frequently occurring adverse reactions (≥ 5% and greater than placebo) were nausea, headache, constipation, dizziness, insomnia, hot flush, hyperhidrosis, vomiting, palpitations, heart rate increased, dry mouth, and hypertension.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9889
Caco-2 permeable+0.5914
P-glycoprotein substrateSubstrate0.5928
P-glycoprotein inhibitor INon-inhibitor0.902
P-glycoprotein inhibitor IINon-inhibitor0.8787
Renal organic cation transporterNon-inhibitor0.8119
CYP450 2C9 substrateNon-substrate0.8494
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.6514
CYP450 1A2 substrateNon-inhibitor0.6383
CYP450 2C9 inhibitorNon-inhibitor0.7697
CYP450 2D6 inhibitorNon-inhibitor0.7718
CYP450 2C19 inhibitorNon-inhibitor0.8587
CYP450 3A4 inhibitorNon-inhibitor0.6327
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7004
Ames testNon AMES toxic0.8013
CarcinogenicityNon-carcinogens0.5456
BiodegradationNot ready biodegradable0.9972
Rat acute toxicity2.6162 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.993
hERG inhibition (predictor II)Non-inhibitor0.6823
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Kitoral
Tablet, film coatedoral100 mg/1
Tablet, film coatedoral12.5 mg/1
Tablet, film coatedoral25 mg/1
Tablet, film coatedoral50 mg/1
Prices
Unit descriptionCostUnit
Savella 100 mg tablet2.13USD tablet
Savella 12.5 mg tablet2.13USD tablet
Savella 25 mg tablet2.13USD tablet
Savella 50 mg tablet2.13USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6602911 No2003-01-142023-01-14Us
US6992110 No2001-11-052021-11-05Us
US7888342 No2001-11-052021-11-05Us
US7994220 No2009-09-192029-09-19Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point179°C Bernstein CD, Albrecht KL, Marcus DA: Milnacipran for fibromyalgia: a useful addition to the treatment armamentarium. Expert Opin Pharmacother. 2013 Mar 19. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/23506481
water solubility19 mg/mLMSDS
Predicted Properties
PropertyValueSource
Water Solubility1.23 mg/mLALOGPS
logP1.72ALOGPS
logP1.42ChemAxon
logS-2.3ALOGPS
pKa (Strongest Basic)9.83ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area46.33 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity73.81 m3·mol-1ChemAxon
Polarizability28.03 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Jean Deregnaucourt, “Use of the (1S,2R) enantiomer of milnacipran for the preparation of a drug.” U.S. Patent US20040259953, issued December 23, 2004.

US20040259953
General References
  1. Leo RJ, Brooks VL: Clinical potential of milnacipran, a serotonin and norepinephrine reuptake inhibitor, in pain. Curr Opin Investig Drugs. 2006 Jul;7(7):637-42. [PubMed:16869117 ]
  2. Sato S, Yamakawa Y, Terashima Y, Ohta H, Asada T: Efficacy of milnacipran on cognitive dysfunction with post-stroke depression: preliminary open-label study. Psychiatry Clin Neurosci. 2006 Oct;60(5):584-9. [PubMed:16958942 ]
  3. Simon LS: Is milnacipran effective in treating pain in patients with fibromyalgia? Nat Clin Pract Rheumatol. 2006 Mar;2(3):126-7. [PubMed:16932669 ]
  4. Soya A, Terao T, Nakajima M, Kojima H, Okamoto T, Inoue Y, Iwakawa M, Shinkai K, Yoshimura R, Ueta Y, Nakamura J: Effects of repeated milnacipran administration on brain serotonergic and noradrenergic functions in healthy volunteers. Psychopharmacology (Berl). 2006 Sep;187(4):526-7. Epub 2006 Jul 8. [PubMed:16830129 ]
  5. King T, Rao S, Vanderah T, Chen Q, Vardanyan A, Porreca F: Differential blockade of nerve injury-induced shift in weight bearing and thermal and tactile hypersensitivity by milnacipran. J Pain. 2006 Jul;7(7):513-20. [PubMed:16814690 ]
  6. Moojen VK, Martins MR, Reinke A, Feier G, Agostinho FR, Cechin EM, Quevedo J: Effects of milnacipran in animal models of anxiety and memory. Neurochem Res. 2006 Apr;31(4):571-7. Epub 2006 May 9. [PubMed:16758367 ]
  7. Moret C, Charveron M, Finberg JP, Couzinier JP, Briley M: Biochemical profile of midalcipran (F 2207), 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology. 1985 Dec;24(12):1211-9. [PubMed:3005901 ]
  8. Briley M, Prost JF, Moret C: Preclinical pharmacology of milnacipran. Int Clin Psychopharmacol. 1996 Sep;11 Suppl 4:9-14. [PubMed:8923122 ]
  9. Puozzo C, Panconi E, Deprez D: Pharmacology and pharmacokinetics of milnacipran. Int Clin Psychopharmacol. 2002 Jun;17 Suppl 1:S25-35. [PubMed:12369608 ]
  10. Leinonen E, Lepola U, Koponen H, Mehtonen OP, Rimon R: Long-term efficacy and safety of milnacipran compared to clomipramine in patients with major depression. Acta Psychiatr Scand. 1997 Dec;96(6):497-504. [PubMed:9421348 ]
  11. Papakostas GI, Fava M: A meta-analysis of clinical trials comparing milnacipran, a serotonin--norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder. Eur Neuropsychopharmacol. 2007 Jan;17(1):32-6. Epub 2006 Jun 8. [PubMed:16762534 ]
  12. Kako Y, Niwa Y, Toyomaki A, Yamanaka H, Kitagawa N, Denda K, Koyama T: A case of adult attention-deficit/hyperactivity disorder alleviated by milnacipran. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Apr 13;31(3):772-5. Epub 2007 Jan 12. [PubMed:17300859 ]
  13. Bernstein CD, Albrecht KL, Marcus DA: Milnacipran for fibromyalgia: a useful addition to the treatment armamentarium. Expert Opin Pharmacother. 2013 May;14(7):905-16. doi: 10.1517/14656566.2013.779670. Epub 2013 Mar 19. [PubMed:23506481 ]
External Links
ATC CodesN06AX17
AHFS Codes
  • 28:16.04.16
  • 28:40
PDB EntriesNot Available
FDA labelDownload (332 KB)
MSDSDownload (83.2 KB)
Interactions
Drug Interactions
Drug
4-MethoxyamphetamineMilnacipran may decrease the antihypertensive activities of 4-Methoxyamphetamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Milnacipran.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the serotonergic activities of Milnacipran.
AcarboseMilnacipran may increase the hypoglycemic activities of Acarbose.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Milnacipran.
AcenocoumarolThe risk or severity of adverse effects can be increased when Milnacipran is combined with Acenocoumarol.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Milnacipran.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Milnacipran.
AcetophenazineThe risk or severity of adverse effects can be increased when Milnacipran is combined with Acetophenazine.
Acetylsalicylic acidMilnacipran may increase the antiplatelet activities of Acetylsalicylic acid.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Milnacipran.
AgmatineMilnacipran may decrease the antihypertensive activities of Agmatine.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Milnacipran.
AlbiglutideMilnacipran may increase the hypoglycemic activities of Albiglutide.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Milnacipran.
AlfentanilAlfentanil may increase the serotonergic activities of Milnacipran.
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Milnacipran.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Milnacipran.
AlogliptinMilnacipran may increase the hypoglycemic activities of Alogliptin.
AlphacetylmethadolAlphacetylmethadol may increase the serotonergic activities of Milnacipran.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Milnacipran.
AlprenololThe serum concentration of Alprenolol can be increased when it is combined with Milnacipran.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Milnacipran.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Milnacipran.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Milnacipran.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Milnacipran.
AmoxapineMilnacipran may increase the serotonergic activities of Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Milnacipran.
ApomorphineMilnacipran may decrease the antihypertensive activities of Apomorphine.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Milnacipran.
ArotinololThe serum concentration of Arotinolol can be increased when it is combined with Milnacipran.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Milnacipran.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Milnacipran.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Milnacipran.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Milnacipran.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Milnacipran.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Milnacipran.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Milnacipran.
BefunololThe serum concentration of Befunolol can be increased when it is combined with Milnacipran.
BendroflumethiazideMilnacipran may increase the hyponatremic activities of Bendroflumethiazide.
BenmoxinBenmoxin may increase the serotonergic activities of Milnacipran.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Milnacipran.
BenzphetamineMilnacipran may decrease the antihypertensive activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Milnacipran.
BetaxololThe serum concentration of Betaxolol can be increased when it is combined with Milnacipran.
BethanidineMilnacipran may decrease the antihypertensive activities of Bethanidine.
BevantololThe serum concentration of Bevantolol can be increased when it is combined with Milnacipran.
BezitramideBezitramide may increase the serotonergic activities of Milnacipran.
BifeprunoxThe risk or severity of adverse effects can be increased when Milnacipran is combined with Bifeprunox.
BisoprololThe serum concentration of Bisoprolol can be increased when it is combined with Milnacipran.
BopindololThe serum concentration of Bopindolol can be increased when it is combined with Milnacipran.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Milnacipran.
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Milnacipran.
BrimonidineMilnacipran may decrease the antihypertensive activities of Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Milnacipran.
BromocriptineMilnacipran may increase the hypoglycemic activities of Bromocriptine.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Milnacipran.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Milnacipran.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Milnacipran.
BufuralolThe serum concentration of Bufuralol can be increased when it is combined with Milnacipran.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Milnacipran.
BupranololThe serum concentration of Bupranolol can be increased when it is combined with Milnacipran.
BuprenorphineBuprenorphine may increase the serotonergic activities of Milnacipran.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Milnacipran.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Milnacipran.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Milnacipran.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Milnacipran.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Milnacipran.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Milnacipran.
ButorphanolButorphanol may increase the serotonergic activities of Milnacipran.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Milnacipran.
CanagliflozinMilnacipran may increase the hypoglycemic activities of Canagliflozin.
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Milnacipran.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Milnacipran.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Milnacipran.
CarfentanilCarfentanil may increase the serotonergic activities of Milnacipran.
CariprazineThe risk or severity of adverse effects can be increased when Milnacipran is combined with Cariprazine.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Milnacipran.
CaroxazoneCaroxazone may increase the serotonergic activities of Milnacipran.
CarteololThe serum concentration of Carteolol can be increased when it is combined with Milnacipran.
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Milnacipran.
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Milnacipran.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Milnacipran.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Milnacipran.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Milnacipran.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Milnacipran.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Milnacipran.
ChlorothiazideMilnacipran may increase the hyponatremic activities of Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Milnacipran.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Milnacipran.
ChlorpropamideMilnacipran may increase the hypoglycemic activities of Chlorpropamide.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Milnacipran.
ChlorthalidoneMilnacipran may increase the hyponatremic activities of Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Milnacipran.
CimetidineThe metabolism of Milnacipran can be decreased when combined with Cimetidine.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Milnacipran.
CitalopramCitalopram may increase the serotonergic activities of Milnacipran.
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Milnacipran.
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Milnacipran.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Milnacipran.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Milnacipran.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Milnacipran.
ClomipramineMilnacipran may increase the serotonergic activities of Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Milnacipran.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Milnacipran.
ClonidineMilnacipran may decrease the antihypertensive activities of Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Milnacipran.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Milnacipran.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Milnacipran.
CodeineCodeine may increase the serotonergic activities of Milnacipran.
CyamemazineThe risk or severity of adverse effects can be increased when Milnacipran is combined with Cyamemazine.
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Milnacipran.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Milnacipran.
CyproheptadineThe therapeutic efficacy of Milnacipran can be decreased when used in combination with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Milnacipran.
DapagliflozinMilnacipran may increase the hypoglycemic activities of Dapagliflozin.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Milnacipran.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Milnacipran.
DapoxetineMilnacipran may increase the serotonergic activities of Dapoxetine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Milnacipran.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Milnacipran.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Milnacipran.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Milnacipran.
DesmopressinThe risk or severity of adverse effects can be increased when Milnacipran is combined with Desmopressin.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Milnacipran is combined with Desvenlafaxine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Milnacipran.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Milnacipran.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Milnacipran.
DexmedetomidineMilnacipran may decrease the antihypertensive activities of Dexmedetomidine.
DextromethorphanMilnacipran may increase the serotonergic activities of Dextromethorphan.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Milnacipran.
DextromoramideDextromoramide may increase the serotonergic activities of Milnacipran.
DextropropoxypheneDextropropoxyphene may increase the serotonergic activities of Milnacipran.
DezocineDezocine may increase the serotonergic activities of Milnacipran.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Milnacipran.
DicoumarolThe risk or severity of adverse effects can be increased when Milnacipran is combined with Dicoumarol.
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Milnacipran.
DigoxinThe risk or severity of adverse effects can be increased when Milnacipran is combined with Digoxin.
DihydrocodeineDihydrocodeine may increase the serotonergic activities of Milnacipran.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Milnacipran.
DihydroergotamineMilnacipran may decrease the antihypertensive activities of Dihydroergotamine.
DihydroetorphineDihydroetorphine may increase the serotonergic activities of Milnacipran.
DihydromorphineDihydromorphine may increase the serotonergic activities of Milnacipran.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Milnacipran.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Milnacipran.
DiphenoxylateDiphenoxylate may increase the serotonergic activities of Milnacipran.
DipivefrinMilnacipran may decrease the antihypertensive activities of Dipivefrin.
DisopyramideMilnacipran may increase the hypoglycemic activities of Disopyramide.
DolasetronDolasetron may increase the serotonergic activities of Milnacipran.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Milnacipran.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Milnacipran.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Milnacipran.
DoxylamineThe risk or severity of adverse effects can be increased when Doxylamine is combined with Milnacipran.
DPDPEDPDPE may increase the serotonergic activities of Milnacipran.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Milnacipran.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Milnacipran.
DroxidopaMilnacipran may decrease the antihypertensive activities of Droxidopa.
DulaglutideMilnacipran may increase the hypoglycemic activities of Dulaglutide.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Milnacipran.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Milnacipran.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Milnacipran.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Milnacipran.
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Milnacipran.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Milnacipran.
EmpagliflozinMilnacipran may increase the hypoglycemic activities of Empagliflozin.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Milnacipran.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Milnacipran.
EphedraMilnacipran may decrease the antihypertensive activities of Ephedra.
EpinephrineMilnacipran may decrease the antihypertensive activities of Epinephrine.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Milnacipran.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Milnacipran.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Milnacipran.
ErgotamineMilnacipran may decrease the antihypertensive activities of Ergotamine.
EscitalopramEscitalopram may increase the serotonergic activities of Milnacipran.
EsmololThe serum concentration of Esmolol can be increased when it is combined with Milnacipran.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Milnacipran.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Milnacipran.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Milnacipran.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Milnacipran.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Milnacipran.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Milnacipran.
Ethyl biscoumacetateThe risk or severity of adverse effects can be increased when Milnacipran is combined with Ethyl biscoumacetate.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Milnacipran.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Milnacipran.
EthylmorphineEthylmorphine may increase the serotonergic activities of Milnacipran.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Milnacipran.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Milnacipran.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Milnacipran.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Milnacipran.
EtomidateMilnacipran may decrease the antihypertensive activities of Etomidate.
EtoperidoneMilnacipran may increase the serotonergic activities of Etoperidone.
EtorphineEtorphine may increase the serotonergic activities of Milnacipran.
ExenatideMilnacipran may increase the hypoglycemic activities of Exenatide.
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Milnacipran.
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Milnacipran.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Milnacipran.
FenfluramineFenfluramine may increase the serotonergic activities of Milnacipran.
FentanylFentanyl may increase the serotonergic activities of Milnacipran.
FentanylThe risk or severity of adverse effects can be increased when Milnacipran is combined with Fentanyl.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Milnacipran.
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Milnacipran.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Milnacipran.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Milnacipran.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Milnacipran.
FluoxetineFluoxetine may increase the serotonergic activities of Milnacipran.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Milnacipran.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Milnacipran.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Milnacipran.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Milnacipran.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Milnacipran.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Milnacipran.
FluvoxamineMilnacipran may increase the serotonergic activities of Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Milnacipran.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Milnacipran.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Milnacipran.
FurazolidoneFurazolidone may increase the serotonergic activities of Milnacipran.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Milnacipran.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Milnacipran.
GalantamineThe metabolism of Galantamine can be decreased when combined with Milnacipran.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Milnacipran.
GliclazideMilnacipran may increase the hypoglycemic activities of Gliclazide.
GlimepirideMilnacipran may increase the hypoglycemic activities of Glimepiride.
GlipizideMilnacipran may increase the hypoglycemic activities of Glipizide.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Milnacipran.
GlyburideMilnacipran may increase the hypoglycemic activities of Glyburide.
GranisetronGranisetron may increase the serotonergic activities of Milnacipran.
GuanabenzMilnacipran may decrease the antihypertensive activities of Guanabenz.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Milnacipran.
GuanfacineMilnacipran may decrease the antihypertensive activities of Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Milnacipran.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Milnacipran.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Milnacipran.
HeroinHeroin may increase the serotonergic activities of Milnacipran.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Milnacipran.
HydracarbazineHydracarbazine may increase the serotonergic activities of Milnacipran.
HydrochlorothiazideMilnacipran may increase the hyponatremic activities of Hydrochlorothiazide.
HydrocodoneHydrocodone may increase the serotonergic activities of Milnacipran.
HydroflumethiazideMilnacipran may increase the hyponatremic activities of Hydroflumethiazide.
HydromorphoneHydromorphone may increase the serotonergic activities of Milnacipran.
HydroxyzineThe risk or severity of adverse effects can be increased when Hydroxyzine is combined with Milnacipran.
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Milnacipran.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Milnacipran.
IndalpineMilnacipran may increase the serotonergic activities of Indalpine.
IndapamideMilnacipran may increase the hyponatremic activities of Indapamide.
IndenololThe serum concentration of Indenolol can be increased when it is combined with Milnacipran.
Insulin AspartMilnacipran may increase the hypoglycemic activities of Insulin Aspart.
Insulin DetemirMilnacipran may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineMilnacipran may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineMilnacipran may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanMilnacipran may increase the hypoglycemic activities of Insulin Human.
Insulin LisproMilnacipran may increase the hypoglycemic activities of Insulin Lispro.
Ioflupane I-123Milnacipran may decrease effectiveness of Ioflupane I 123 as a diagnostic agent.
IproclozideIproclozide may increase the serotonergic activities of Milnacipran.
IproniazidIproniazid may increase the serotonergic activities of Milnacipran.
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Milnacipran.
IsocarboxazidThe risk or severity of adverse effects can be increased when Milnacipran is combined with Isocarboxazid.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Milnacipran.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Milnacipran.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Milnacipran.
KetobemidoneKetobemidone may increase the serotonergic activities of Milnacipran.
L-TryptophanL-Tryptophan may increase the serotonergic activities of Milnacipran.
LabetalolThe serum concentration of Labetalol can be increased when it is combined with Milnacipran.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Milnacipran.
LanreotideMilnacipran may increase the hypoglycemic activities of Lanreotide.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Milnacipran.
LevobunololThe serum concentration of Levobunolol can be increased when it is combined with Milnacipran.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Milnacipran.
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Milnacipran.
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Milnacipran.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Milnacipran.
Levomethadyl AcetateLevomethadyl Acetate may increase the serotonergic activities of Milnacipran.
LevomilnacipranMilnacipran may increase the serotonergic activities of Levomilnacipran.
LevorphanolLevorphanol may increase the serotonergic activities of Milnacipran.
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Milnacipran.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Milnacipran.
LinezolidLinezolid may increase the serotonergic activities of Milnacipran.
LinezolidThe risk or severity of adverse effects can be increased when Milnacipran is combined with Linezolid.
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Milnacipran.
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Milnacipran.
LiraglutideMilnacipran may increase the hypoglycemic activities of Liraglutide.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Milnacipran.
LofentanilLofentanil may increase the serotonergic activities of Milnacipran.
LofexidineMilnacipran may decrease the antihypertensive activities of Lofexidine.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Milnacipran.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Milnacipran.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Milnacipran.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Milnacipran.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Milnacipran.
Lu AA21004Milnacipran may increase the serotonergic activities of Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Milnacipran.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Milnacipran.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Milnacipran.
MebanazineMebanazine may increase the serotonergic activities of Milnacipran.
MecaserminMilnacipran may increase the hypoglycemic activities of Mecasermin.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Milnacipran.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Milnacipran.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Milnacipran.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Milnacipran.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Milnacipran.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Milnacipran.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Milnacipran.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Milnacipran.
MetforminMilnacipran may increase the hypoglycemic activities of Metformin.
MethadoneThe metabolism of Methadone can be decreased when combined with Milnacipran.
MethadoneMethadone may increase the serotonergic activities of Milnacipran.
Methadyl AcetateMethadyl Acetate may increase the serotonergic activities of Milnacipran.
MethamphetamineMilnacipran may decrease the antihypertensive activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Milnacipran.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Milnacipran.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Milnacipran.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Milnacipran.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Milnacipran.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Milnacipran.
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Milnacipran.
MethyclothiazideMilnacipran may increase the hyponatremic activities of Methyclothiazide.
Methylene blueMilnacipran may increase the serotonergic activities of Methylene blue.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Milnacipran.
MetipranololThe serum concentration of Metipranolol can be increased when it is combined with Milnacipran.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Milnacipran.
MetolazoneMilnacipran may increase the hyponatremic activities of Metolazone.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Milnacipran.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Milnacipran.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Milnacipran.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Milnacipran.
MifepristoneMilnacipran may increase the hypoglycemic activities of Mifepristone.
MiglitolMilnacipran may increase the hypoglycemic activities of Miglitol.
MinaprineMinaprine may increase the serotonergic activities of Milnacipran.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Milnacipran.
MoclobemideMoclobemide may increase the serotonergic activities of Milnacipran.
MoclobemideThe risk or severity of adverse effects can be increased when Milnacipran is combined with Moclobemide.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Milnacipran.
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Milnacipran.
MorphineMorphine may increase the serotonergic activities of Milnacipran.
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Milnacipran.
NadololThe serum concentration of Nadolol can be increased when it is combined with Milnacipran.
NalbuphineNalbuphine may increase the serotonergic activities of Milnacipran.
NaphazolineMilnacipran may decrease the antihypertensive activities of Naphazoline.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Milnacipran.
NateglinideMilnacipran may increase the hypoglycemic activities of Nateglinide.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Milnacipran.
NialamideNialamide may increase the serotonergic activities of Milnacipran.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Milnacipran.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Milnacipran.
NorepinephrineMilnacipran may decrease the antihypertensive activities of Norepinephrine.
NormethadoneNormethadone may increase the serotonergic activities of Milnacipran.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Milnacipran.
OctamoxinOctamoxin may increase the serotonergic activities of Milnacipran.
OctreotideMilnacipran may increase the hypoglycemic activities of Octreotide.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Milnacipran.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Milnacipran.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Milnacipran.
OpiumOpium may increase the serotonergic activities of Milnacipran.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Milnacipran.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Milnacipran.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Milnacipran.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Milnacipran.
OxprenololThe serum concentration of Oxprenolol can be increased when it is combined with Milnacipran.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Milnacipran.
OxycodoneOxycodone may increase the serotonergic activities of Milnacipran.
OxymetazolineMilnacipran may decrease the antihypertensive activities of Oxymetazoline.
OxymorphoneOxymorphone may increase the serotonergic activities of Milnacipran.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Milnacipran.
PalonosetronPalonosetron may increase the serotonergic activities of Milnacipran.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Milnacipran.
PargylinePargyline may increase the serotonergic activities of Milnacipran.
ParoxetineParoxetine may increase the serotonergic activities of Milnacipran.
PasireotideMilnacipran may increase the hypoglycemic activities of Pasireotide.
PenbutololThe serum concentration of Penbutolol can be increased when it is combined with Milnacipran.
PentamidineMilnacipran may increase the hypoglycemic activities of Pentamidine.
PentazocinePentazocine may increase the serotonergic activities of Milnacipran.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Milnacipran.
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Milnacipran.
PergolideMilnacipran may decrease the antihypertensive activities of Pergolide.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Milnacipran.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Milnacipran.
PethidinePethidine may increase the serotonergic activities of Milnacipran.
PethidineThe risk or severity of adverse effects can be increased when Milnacipran is combined with Pethidine.
PhenelzinePhenelzine may increase the serotonergic activities of Milnacipran.
PhenelzineThe risk or severity of adverse effects can be increased when Milnacipran is combined with Phenelzine.
PhenindioneThe risk or severity of adverse effects can be increased when Milnacipran is combined with Phenindione.
PheniprazinePheniprazine may increase the serotonergic activities of Milnacipran.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Milnacipran.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Milnacipran.
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Milnacipran.
PhenprocoumonThe risk or severity of adverse effects can be increased when Milnacipran is combined with Phenprocoumon.
PhenylpropanolamineMilnacipran may decrease the antihypertensive activities of Phenylpropanolamine.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Milnacipran.
PimozideThe risk or severity of adverse effects can be increased when Milnacipran is combined with Pimozide.
PindololThe serum concentration of Pindolol can be increased when it is combined with Milnacipran.
PioglitazoneMilnacipran may increase the hypoglycemic activities of Pioglitazone.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Milnacipran.
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Milnacipran.
PirlindolePirlindole may increase the serotonergic activities of Milnacipran.
PivhydrazinePivhydrazine may increase the serotonergic activities of Milnacipran.
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Milnacipran.
PolythiazideMilnacipran may increase the hyponatremic activities of Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Milnacipran.
PractololThe serum concentration of Practolol can be increased when it is combined with Milnacipran.
PramlintideMilnacipran may increase the hypoglycemic activities of Pramlintide.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Milnacipran.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Milnacipran.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Milnacipran.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Milnacipran.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Milnacipran.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Milnacipran.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Milnacipran.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Milnacipran.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Milnacipran.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Milnacipran.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Milnacipran.
PropericiazineThe risk or severity of adverse effects can be increased when Milnacipran is combined with Propericiazine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Milnacipran.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Milnacipran.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Milnacipran.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Milnacipran.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Milnacipran.
PseudoephedrineMilnacipran may decrease the antihypertensive activities of Pseudoephedrine.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Milnacipran.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Milnacipran.
QuinethazoneMilnacipran may increase the hyponatremic activities of Quinethazone.
QuinineMilnacipran may increase the hypoglycemic activities of Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Milnacipran.
RasagilineRasagiline may increase the serotonergic activities of Milnacipran.
RasagilineThe risk or severity of adverse effects can be increased when Milnacipran is combined with Rasagiline.
RemifentanilRemifentanil may increase the serotonergic activities of Milnacipran.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Milnacipran.
RepaglinideMilnacipran may increase the hypoglycemic activities of Repaglinide.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Milnacipran.
RisperidoneThe metabolism of Risperidone can be decreased when combined with Milnacipran.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Milnacipran.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Milnacipran.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Milnacipran.
RopiniroleMilnacipran may decrease the antihypertensive activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Milnacipran.
RosiglitazoneMilnacipran may increase the hypoglycemic activities of Rosiglitazone.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Milnacipran.
SafrazineSafrazine may increase the serotonergic activities of Milnacipran.
SaxagliptinMilnacipran may increase the hypoglycemic activities of Saxagliptin.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Milnacipran.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Milnacipran.
SelegilineSelegiline may increase the serotonergic activities of Milnacipran.
SelegilineThe risk or severity of adverse effects can be increased when Milnacipran is combined with Selegiline.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Milnacipran.
SertralineSertraline may increase the serotonergic activities of Milnacipran.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Milnacipran.
SitagliptinMilnacipran may increase the hypoglycemic activities of Sitagliptin.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Milnacipran.
SotalolThe serum concentration of Sotalol can be increased when it is combined with Milnacipran.
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Milnacipran.
SufentanilSufentanil may increase the serotonergic activities of Milnacipran.
SulfadiazineMilnacipran may increase the hypoglycemic activities of Sulfadiazine.
SulfamethoxazoleMilnacipran may increase the hypoglycemic activities of Sulfamethoxazole.
SulfisoxazoleMilnacipran may increase the hypoglycemic activities of Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Milnacipran.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Milnacipran.
SunitinibMilnacipran may increase the hypoglycemic activities of Sunitinib.
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Milnacipran.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Milnacipran.
TapentadolTapentadol may increase the serotonergic activities of Milnacipran.
TapentadolThe risk or severity of adverse effects can be increased when Milnacipran is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Milnacipran.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Milnacipran.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Milnacipran is combined with Tedizolid Phosphate.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Milnacipran.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Milnacipran.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Milnacipran.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Milnacipran.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Milnacipran.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Milnacipran.
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Milnacipran.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Milnacipran.
ThioproperazineThe risk or severity of adverse effects can be increased when Milnacipran is combined with Thioproperazine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Milnacipran.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Milnacipran.
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Milnacipran.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Milnacipran.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Milnacipran.
TimololThe serum concentration of Timolol can be increased when it is combined with Milnacipran.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Milnacipran.
TizanidineMilnacipran may decrease the antihypertensive activities of Tizanidine.
TolazamideMilnacipran may increase the hypoglycemic activities of Tolazamide.
TolbutamideMilnacipran may increase the hypoglycemic activities of Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Milnacipran.
ToloxatoneToloxatone may increase the serotonergic activities of Milnacipran.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Milnacipran.
TramadolMilnacipran may increase the neuroexcitatory activities of Tramadol.
TramadolTramadol may increase the serotonergic activities of Milnacipran.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Milnacipran.
TranylcypromineTranylcypromine may increase the serotonergic activities of Milnacipran.
TranylcypromineThe risk or severity of adverse effects can be increased when Milnacipran is combined with Tranylcypromine.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Milnacipran.
TrazodoneMilnacipran may increase the serotonergic activities of Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Milnacipran.
TrichlormethiazideMilnacipran may increase the hyponatremic activities of Trichlormethiazide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Milnacipran.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Milnacipran.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Milnacipran.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Milnacipran.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Milnacipran.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Milnacipran.
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Milnacipran.
VilazodoneMilnacipran may increase the serotonergic activities of Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Milnacipran.
VortioxetineMilnacipran may increase the serotonergic activities of Vortioxetine.
WarfarinThe risk or severity of adverse effects can be increased when Milnacipran is combined with Warfarin.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Milnacipran.
XylometazolineMilnacipran may decrease the antihypertensive activities of Xylometazoline.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Milnacipran.
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Milnacipran.
ZimelidineZimelidine may increase the serotonergic activities of Milnacipran.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Milnacipran.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Milnacipran.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Milnacipran.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Milnacipran.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Milnacipran.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Milnacipran.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Milnacipran.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Milnacipran.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Leo RJ, Brooks VL: Clinical potential of milnacipran, a serotonin and norepinephrine reuptake inhibitor, in pain. Curr Opin Investig Drugs. 2006 Jul;7(7):637-42. [PubMed:16869117 ]
  2. Moret C, Charveron M, Finberg JP, Couzinier JP, Briley M: Biochemical profile of midalcipran (F 2207), 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology. 1985 Dec;24(12):1211-9. [PubMed:3005901 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Leo RJ, Brooks VL: Clinical potential of milnacipran, a serotonin and norepinephrine reuptake inhibitor, in pain. Curr Opin Investig Drugs. 2006 Jul;7(7):637-42. [PubMed:16869117 ]
  2. Moret C, Charveron M, Finberg JP, Couzinier JP, Briley M: Biochemical profile of midalcipran (F 2207), 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology. 1985 Dec;24(12):1211-9. [PubMed:3005901 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated cation channel activity
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. This protein plays a key role in synaptic plasticity, synaptogenesis, excitotoxicity, memory acquisition and learning. It mediates neuronal functions in glutamate neurotransmission. Is involved in the cell surface targeting of NMDA receptors (By similarity).
Components:
NameUniProt IDDetails
Glutamate receptor ionotropic, NMDA 1Q05586 Details
Glutamate receptor ionotropic, NMDA 2AQ12879 Details
Glutamate receptor ionotropic, NMDA 2BQ13224 Details
Glutamate receptor ionotropic, NMDA 2CQ14957 Details
Glutamate receptor ionotropic, NMDA 2DO15399 Details
Glutamate receptor ionotropic, NMDA 3AQ8TCU5 Details
Glutamate receptor ionotropic, NMDA 3BO60391 Details
References
  1. Kohno T, Kimura M, Sasaki M, Obata H, Amaya F, Saito S: Milnacipran inhibits glutamatergic N-methyl-D-aspartate receptor activity in spinal dorsal horn neurons. Mol Pain. 2012 Jun 19;8:45. doi: 10.1186/1744-8069-8-45. [PubMed:22716121 ]
  2. Shuto S, Takada H, Mochizuki D, Tsujita R, Hase Y, Ono S, Shibuya N, Matsuda A: (+/-)-(Z)-2-(aminomethyl)-1-phenylcyclopropanecarboxamide derivatives as a new prototype of NMDA receptor antagonists. J Med Chem. 1995 Jul 21;38(15):2964-8. [PubMed:7636857 ]
Comments
comments powered by Disqus
Drug created on October 21, 2007 16:23 / Updated on September 28, 2016 02:26